Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma
| العنوان: | Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma |
|---|---|
| المؤلفون: | Olivier Chinot, Whitney B. Pope, Tracy T. Batchelor, Roger Henriksson, Sarah J. Nelson, Jennie Taylor, Susan M. Chang, Patrick Y. Wen, Arnav Mehta, Elizabeth R. Gerstner, Ryo Nishikawa, Brian M. Alexander, Timothy J. Kaufmann, Ingo K. Mellinghoff, Benjamin M. Ellingson, Keith L. Ligon, Howard Colman, John de Groot, Josep Garcia, Robert J. Young, Frank Saran, Warren P. Mason, Nicholas Butowski, Raymond Y. Huang, Isabel Arrillaga-Romany, Evanthia Galanis, Timothy F. Cloughesy, Lauren E. Abrey, Michael D. Prados, Wolfgang Wick, David A. Reardon, Rivkah Colen |
| المساهمون: | Département de neurooncologie, Hôpital de la Timone [CHU - APHM] (TIMONE), Department of Radiation Sciences, Oncology, Umeå University, Department of Neurooncology, Heidelberg University Hospital [Heidelberg], Hadassah Hebrew University Medical Center [Jerusalem], Massachusetts General Hospital [Boston], Loughborough University, School of Environment and Technology, University of Sussex, Department of Molecular Medicine, Mayo Clinic, Hôpital de la Timone [CHU - APHM] ( TIMONE ), Massachusetts General Hospital [Boston] ( MGH ) |
| المصدر: | Neuro-Oncology Neuro-Oncology, Oxford University Press (OUP), 2018, ⟨10.1093/neuonc/noy053⟩ Neuro-Oncology, Oxford University Press (OUP), 2018, 〈10.1093/neuonc/noy053〉 Neuro-oncology, vol 20, iss 9 Ellingson, BM; Abrey, LE; Nelson, SJ; Kaufmann, TJ; Garcia, J; Chinot, O; et al.(2018). Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. NEURO-ONCOLOGY, 20(9), 1240-1250. doi: 10.1093/neuonc/noy053. UCLA: Retrieved from: http://www.escholarship.org/uc/item/0v78z01zTest |
| بيانات النشر: | HAL CCSD, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | Oncology, Male, Cancer Research, contrast-enhancing tumor volume, [SDV]Life Sciences [q-bio], Contrast Media, 0302 clinical medicine, Antineoplastic Combined Chemotherapy Protocols, ComputingMilieux_MISCELLANEOUS, Cancer, Vorinostat, Chemoradiotherapy, Middle Aged, Prognosis, Magnetic Resonance Imaging, 3. Good health, Survival Rate, 030220 oncology & carcinogenesis, Residual, 6.1 Pharmaceuticals, Female, medicine.drug, medicine.medical_specialty, Prognostic factor, Bevacizumab, Clinical Trials and Supportive Activities, Oncology and Carcinogenesis, Newly diagnosed, bevacizumab, Imaging data, GBM, 03 medical and health sciences, Rare Diseases, Clinical Research, Internal medicine, medicine, Overall survival, Temozolomide, Humans, Oncology & Carcinogenesis, Retrospective Studies, Postoperative Care, clinical trials, [ SDV ] Life Sciences [q-bio], business.industry, T1 subtraction, Neurosciences, O-6-methylguanine-DNA methyltransferase, Evaluation of treatments and therapeutic interventions, medicine.disease, Image Enhancement, new glioblastoma, nervous system diseases, Brain Disorders, Clinical trial, Brain Cancer, Neoplasm, Neurology (clinical), business, Glioblastoma, 030217 neurology & neurosurgery, Follow-Up Studies |
| الوصف: | BackgroundIn the current study, we pooled imaging data in newly diagnosed glioblastoma (GBM) patients from international multicenter clinical trials, single institution databases, and multicenter clinical trial consortiums to identify the relationship between postoperative residual enhancing tumor volume and overall survival (OS).MethodsData from 1511 newly diagnosed GBM patients from 5 data sources were included in the current study: (i) a single institution database from UCLA (N = 398; Discovery); (ii) patients from the Ben and Cathy Ivy Foundation for Early Phase Clinical Trials Network Radiogenomics Database (N = 262 from 8 centers; Confirmation); (iii) the chemoradiation placebo arm from an international phase III trial (AVAglio; N = 394 from 120 locations in 23 countries; Validation); (iv) the experimental arm from AVAglio examining chemoradiation plus bevacizumab (N = 404 from 120 locations in 23 countries; Exploratory Set 1); and (v) an Alliance (N0874) phase I/II trial of vorinostat plus chemoradiation (N = 53; Exploratory Set 2). Postsurgical, residual enhancing disease was quantified using T1 subtraction maps. Multivariate Cox regression models were used to determine influence of clinical variables, O6-methylguanine-DNA methyltransferase (MGMT) status, and residual tumor volume on OS.ResultsA log-linear relationship was observed between postoperative, residual enhancing tumor volume and OS in newly diagnosed GBM treated with standard chemoradiation. Postoperative tumor volume is a prognostic factor for OS (P < 0.01), regardless of therapy, age, and MGMT promoter methylation status.ConclusionPostsurgical, residual contrast-enhancing disease significantly negatively influences survival in patients with newly diagnosed GBM treated with chemoradiation with or without concomitant experimental therapy. |
| وصف الملف: | application/pdf |
| اللغة: | English |
| تدمد: | 1522-8517 1523-5866 |
| الوصول الحر: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f5bde2fd7ff93ddc9c95a933bfa0dc0aTest https://hal-amu.archives-ouvertes.fr/hal-01814367Test |
| حقوق: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f5bde2fd7ff93ddc9c95a933bfa0dc0a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 15228517 15235866 |
|---|